摘要:
The invention concerns pharmaceutical compositions containing as the active substance estra-1,3,5(10)-triene derivatives with an R-SO2-O- group on the 3 C-atom, R being an R1R2N- group in which R?1 and R2¿, independently of each other, are a hydrogen atom, an alkyl group with 1 to 5 C-atoms or, together with the N-atom, a polymethyleneimino group with 4 to 6 C-atoms or a morpholino group. The compounds described are suitable for use in hormonal contraception and in climacteric hormone-replacement therapy (HRT), as well as in the treatment of gynaecological and andrological conditions. The compounds described thus only have a low hepatic oestrogenicity.
摘要:
New non-estrogenic estradiol derivatives with an antioxidant effect are disclosed. These estradiol derivatives, which have no estrogenic effect but a high antioxidant effect, are potentially useful as non-estrogenic antioxidants, in particular for postmenopausal women and for men. Moreover, the disclosed compounds are potential aromatase and sulfatase inhibitors.
摘要:
The invention relates to novel sulphamate derivatives of 1,3,5(10)-estratriene derivatives of general formula (I) in which the 3-sulphamate group is acylated, sulphonated or amido-sulphonated. Also disclosed are methods of producing these compounds and pharmaceutical compounds containing them. The claimed compounds have estrogen-like properties.
摘要:
The invention relates to novel sulphamate derivatives of 1,3,5(10)-estratriene derivatives of general formula (I) in which the 3-sulphamate group is acylated, sulphonated or amido-sulphonated. Also disclosed are methods of producing these compounds and pharmaceutical compounds containing them. The claimed compounds have estrogen-like properties.
摘要:
The invention relates to pharmaceutical combinations for compensating for an absolute and relative testosterone deficiency in men while simultaneously preventing the development of benign prostatic hypertrophy (BPH) or of prostatic cancer. The inventive combinations contain a natural or synthetic androgen combined with a gestagen, an antigestagen, an antiestrogen, a GnRH analog, a testosterone-5α-reductase inhibitor, an α-adrenergic blocking agent or a phosphodiesterase inhibitor. Compared to the inventive combinations, each active ingredient cannot carry out the desired objective alone.
摘要:
New non-estrogenic estradiol derivatives with an antioxidant effect are disclosed. These estradiol derivatives, which have no estrogenic effect but a high antioxidant effect, are potentially useful as non-estrogenic antioxidants, in particular for postmenopausal women and for men. Moreover, the disclosed compounds are potential aromatase and sulfatase inhibitors.
标题翻译:14,15-CYCLOPROPANOSTEROIDE DER 19-NORANDROSTAN-REIHE,VERFAHREN ZU IHRER HERSTELLUNG UND DIESE VERBINDUNGEN ENTHALTENDE PHARMAZUUTISCHE ZUSAMMENSETZUNGEN
摘要:
The invention relates to novel 14,15-cyclopropanosteroids of the 19-norandrostane series having the general formula (I), preparation thereof and pharmaceutical compositions containing said compounds. Compounds of the formula (I) have an interesting androgen/gestagen mixture profile. The activity of the androgens or the gestagens can predominate, depending on the respective substitution.
摘要:
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological disorder such as endometriosis, uterine fibroids, postoperative peritoneal adhesions, dysfunctional bleeding (metrorrhagia, menorrhagia) and dysmenorrhea; b) for the prevention of gynecological disorders such as postoperative, peritoneal adhesions, dysfunctional uterine bleeding (metrorrhagia, menorrhagia) and dysmenorrhea; and c) a method of treatment and prevention of the above mentioned disorders in a female, preferably in a human female, in need of treatment or prevention of one or more of these disorders, with an effective amount of a mesoprogestin. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiprogestins. The daily dose of mesoprogestin is 0.5 to 100 mg, preferably 5.0 to 50 mg and most preferably 10 to 25 mg. J867, J912, J956 and J1042 are the mesoprogestins preferred according to the invention.
摘要:
The invention relates to novel 15-methyl-cyclopropanosteroids of general formula (I), wherein R1 represents a hydrogen atom, an alkyl group, an acyl group, or a sulfamoyl group, R2 and R3 represent independently from each other a hydrogen atom or a halogen atom, R4 represents an oxo group or a hydrogen atom and a hydroxy group, and the 14,15-methylene group has either an alpha or beta configuration, wherein the 15-methyl group is in beta position when the 14,15-methylene group is arranged in alpha position and vice-versa. The invention also relates to 15 methyl-pentasteroids which are suitable as parent compounds in the production of the inventive 15-methyl-cyclopropanosteroids. The invention further relates to a method for the production of the inventive 15-methyl-cyclopropanosteroids and 15-methylpentaensteroids.
摘要:
The invention relates to novel C13-substituted estra-1,3,5(10)-triene-3-yl-sulfamates of the general formula (I), in which R1 represents the acyl radical, oxycarbonyl radical, aminocarbonyl radical, sulfonyl radical or aminosulfonyl radical and R15 stands for C2-C5 alkyl, C2-C5 alkenyl or C2-C5-alkinyl. The invention also relates to a method for producing these compounds and to pharmaceutical compositions which contain said compounds. The inventive compounds of the general formula (I) inhibit the activity of steroid sulfatases (EC 3.1.6.2) and do not exhibit any oestrogenic action.